For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring a…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Search Posts
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. AUTOMOBILITY Forbes reports on the National Highway Traffic Safety Administration’s plan to update its fuel economy…
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. E-COMMERCE Real estate company Remax announces the creation of an online database of homes for sale…
Op-Eds
Tobacco Deal-Breaker?
“No State shall, without the Consent of Congress, . . . enter into any Agreement or Compact with another State.” —- U.S. Constitution, Article I,…
Citation
Tobacco Deal-Breaker?
Newsletter
The Competitive Enterprise Institute Daily Update
1. HEALTH & SAFETY A Texas court case against the drug maker Merck & Co. over the safety of the painkiller Vioxx…
Op-Eds
Are We in a Brave New World of “Personalized” Medicine?
BiDil, a new drug labeled for treatment of blacks with severe heart failure, has begun to arrive in pharmacies. Approved by FDA in…